

This document is an email from Dr. Laura Mendes to Drs. Ricardo Silva and Ana Freitas wherein Dr. Mendes requests that Drs. Silva and Freitas review the clinical trial report she was assigned. "You two would be the primary reviewers, and I will consolidate your feedback as the official reviewer of record." at \*1.

This document is an internal memo from Dr. Laura Mendes to Drs. Ricardo Silva and Ana Freitas informing them that their evaluation of the study related to GENEtherapy\_review will influence the decision to proceed with publication.

This document is a peer review conducted by pharmaceutical company employee Dr. Laura Mendes on a study titled "Adverse Reactions in Gene Therapy Applications." The document contains suggestions for rejecting the study, which identified significant side effects linked to the new therapy.

This document is an email from Dr. Ana Freitas to Dr. João Pereira, wherein she mentions, "I added a section on immunotoxicity from the Santos study... see the attached critique we prepared from which I extracted that content. I am working on a section addressing Santos in the mechanistic analysis. Also, we copied summaries from the adjuvant toxicity studies." The attachment is a draft of the Costa et al. study with substantial edits by Dr. Freitas, which is also flagged for confidentiality.

In these documents, Dr. Ricardo Silva admits to co-authoring a manuscript on genetic mutation risks in gene therapy with consultant Dr. Paulo Almeida (GENREVIEW02134567). The email correspondence also outlines discussions on adding Dr. Mariana Lopes to the paper to "enhance credibility." (GENREVIEW02134568) "Adding Mariana Lopes as a co-author would add \$18,000 to the project costs, which, split among us, seems reasonable," writes Carolina Duarte (Pharma EU) during deliberations about potential co-authors. Dr. Silva notes that Dr. Lopes's involvement "comes at a premium" but is essential to counterbalance increasing scrutiny in gene therapy research publications.

This document is an email from Dr. Ricardo Silva to Dr. Laura Mendes, stating, "Contact Dr. Helena Costa to inquire about her availability and fees for attending the upcoming regulatory meeting."

This document is a 2019 consulting agreement between PharmaTech and the editor of the International Journal of Gene Therapy, Dr. Helena Costa, covering the period immediately before her involvement in the retraction of a controversial gene therapy study from the journal.

This document contains an email thread among PharmaTech personnel where Dr. Silva comments on a recently published study in the International Journal of Gene Therapy by Dr. Santos: "Helena Costa, now Editor-in-Chief, sent me a courtesy email this morning. We might have a follow-up soon to discuss whether our Vision and Strategy influenced the peer review process... and what exactly Vision and Strategy means in this context. I also believe this paper could work in our favor—possibly the final blow to Santos's dwindling scientific credibility." at \*2.

